December 15, 2009; 73 (24) Editorials
APOE ε4 and bapineuzumab
Infusing pharmacogenomics into Alzheimer disease therapeutics
Dan Kaufer, Sam Gandy
First published November 18, 2009, DOI: https://doi.org/10.1212/WNL.0b013e3181c6784a
APOE ε4 and bapineuzumab
Infusing pharmacogenomics into Alzheimer disease therapeutics
Dan Kaufer, Sam Gandy
Neurology Dec 2009, 73 (24) 2052-2053; DOI: 10.1212/WNL.0b013e3181c6784a
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 73 no. 24 2052-2053
PubMed:
Print ISSN:
Online ISSN:
History:
- First Published November 18, 2009.
Article Versions
- Previous version (November 18, 2009 - 12:51).
- You are viewing the most recent version of this article.
Copyright & Usage:
© 2009
Author Disclosures
- Dan Kaufer, MD and
- Sam Gandy, MD, PhD
- Dan Kaufer, MD and
- Sam Gandy, MD, PhD
- From the Department of Neurology (D.K.), University of North Carolina, Chapel Hill; Departments of Neurology and Psychiatry (S.G.), Mount Sinai School of Medicine, New York; and James J. Peters Veterans Affairs Medical Center (S.G.), Bronx, NY.
- Address correspondence and reprint requests to Dr. Dan Kaufer, CB 7025, 3129 POB, 170 Manning Drive, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; kauferd{at}neurology.unc.edu
Article usage
Cited By...
Letters: Rapid online correspondence
No comments have been published for this article.
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Dr. Jeffrey Allen and Dr. Nicholas Purcell
► Watch
Related Articles
Alert Me
Recommended articles
-
Articles
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer diseaseS. Salloway, R. Sperling, S. Gilman et al.Neurology, November 18, 2009 -
Articles
Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophyA. van der Walt, J. Stankovich, M. Bahlo et al.Neurology, September 28, 2009 -
Article
APOE ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementiaSaira Saeed Mirza, Usman Saeed, Jo Knight et al.Neurology, October 01, 2019 -
Article
APOE polymorphisms influence longitudinal lipid trends preceding intracerebral hemorrhageChia-Ling Phuah, Miriam R. Raffeld, Alison M. Ayres et al.Neurology: Genetics, June 23, 2016